CYC fundamentals

Key facts

Market capitalization‪221.72 M‬AUD
Basic EPS (TTM)−0.10AUD
Founded2005
CEOJames M. McBrayer
About

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in diagnostic imaging in lung health. It manufactures and sells medical devices and pharmaceutical products. It operates through Technegas and Molecular Imaging segments. The Technegas segment supplies diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The company was founded in 1984 and is headquartered in Kingsgrove, Australia.

Ownership
‪‪111.14 M‬‬
Free Float shares
‪‪59.35 M‬‬ (53.41%)
Closely held shares
‪‪51.78 M‬‬ (46.59%)
Free Float shares
‪‪59.35 M‬‬ (53.41%)
Closely held shares
‪‪51.78 M‬‬ (46.59%)
Capital structure
Market cap
‪‪221.72 M‬‬
Debt
‪‪5.57 M‬‬
Cash & equivalents
‪‪27.56 M‬‬
Enterprise value
‪‪199.73 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪221.72 M‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
8.35x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
8.35x
Valuation ratios
H1 '22
H2 '22
H1 '23
H2 '23
H1 '24
‪0.00‬
‪2.00‬
‪4.00‬
‪6.00‬
‪8.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−63%‬
‪−51%‬
‪−39%‬
‪−27%‬
‪−15%‬
H1 '22
H2 '22
H1 '23
H2 '23
H1 '24
‪‪−8.00 M‬‬
‪0.00‬
‪‪8.00 M‬‬
‪‪16.00 M‬‬
‪‪24.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−14.00 M‬‬
‪‪−7.00 M‬‬
‪0.00‬
‪‪7.00 M‬‬
‪‪14.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−14.00 M‬‬
‪‪−7.00 M‬‬
‪0.00‬
‪‪7.00 M‬‬
‪‪14.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Technegas
By country
Period: 2023
Europe
Asia Pacific
Canada
Other

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
H1 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪0.00‬
‪‪4.50 M‬‬
‪‪9.00 M‬‬
‪‪13.50 M‬‬
‪‪18.00 M‬‬
Actual
Estimate
Earnings
Next:Feb 19
H1 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪−0.08‬
‪−0.06‬
‪−0.04‬
‪−0.02‬
‪0.00‬
Actual

Dividends

Dividend yield, history and sustainability

Dividend summary
0.00%
Payout ratio (TTM)
Dividend yield TTM
0.00%
Last payment
0.005
Last ex-date
Sep 1, 2023
Dividend history
‪0.25%‬
‪0.41%‬
‪0.57%‬
‪0.73%‬
‪0.89%‬
2019
2020
2021
2022
2023
‪0.00‬
‪0.00‬
‪0.01‬
‪0.01‬
‪0.01‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
H1 '22
H2 '22
H1 '23
H2 '23
H1 '24
‪‪−10.00 M‬‬
‪0.00‬
‪‪10.00 M‬‬
‪‪20.00 M‬‬
‪‪30.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪12.00 M‬‬
‪‪24.00 M‬‬
‪‪36.00 M‬‬
‪‪48.00 M‬‬
Assets
Liabilities